LASIX ONYU

Launch

furosemide

NDASUBCUTANEOUSSOLUTION
Approved
Oct 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

12.1 Mechanism of Action Furosemide primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle. The high degree of diuresis is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory…

Pharmacologic Class:

Loop Diuretic

Clinical Trials (5)

NCT07431866Phase 1Not Yet Recruiting

A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)

Started Apr 2026
39 enrolled
Healthy
NCT06941415Phase 3Not Yet Recruiting

Bumetanide vs. Furosemide in Cirrhosis

Started Mar 2026
500 enrolled
Cirrhosis
NCT06504862Phase 1Completed

A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood

Started Aug 2024
32 enrolled
Healthy
NCT06491550Phase 1Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

Started Jul 2024
91 enrolled
Healthy Participants
NCT05741372N/ACompleted

A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Started Sep 2023
28 enrolled
Liver Cirrhosis